Nurse Practitioner exam review questions and answers updated 2026

Nurse Practitioner exam review
questions and answers updated 2026
PrimaryBpreventionB-BAnswerpreventBtheBonsetBorBacquisitionBofBaBgivenBdisease.B



educationBandBcounseling



theBmostBeffectiveBformBofBhealthcare.



SecondaryBpreventionB-
BAnswertoBidentifyBandBtreatBasymptomaticBpersonsBwhoBhaveBriskBfactorsBforBaBgivenBdisea
seBorBinBpreclinicalBdisease.B



screening,B

BPBforBHTN

LipidBProfileBforBHLD



TertiaryBpreventionB-BAnswermanagementBofBanBestablishedBdisease.B

minimizeBdisease



medicationsBandBlifestyleBmodificationBtoBnormalizeB



aimedBatBimprovingBorBminimizingBdisease-relatedBsymptoms.



ActiveBimmunityBisBdefinedBasB-BAnswerresistanceBdevelopedBinBresponseBtoBanBantigen.



WhichBofBtheBfollowingBstatementsBbestBdescribesBzanamivirB(Relenza)BorBoseltamivirB(Tamiflu
)BuseBinBtheBcareBofBpatientsBwithBorBatBriskBforBinfluenza?B-
BAnswerInitiationBofBtherapyBearlyBinBacuteBinfluenzaBillnessBcanBhelpBminimizeBtheBseverityB
ofBdiseaseBwhenBtheBillnessBisBcausedBbyBaBnonresistantBviralBstrain.



PreventiveBServicesBRecommendedBbyBtheBUSPSTFB-BAnswer

,PreventiveBServicesBRecommendedBbyBtheBUSPSTFB2B-BAnswer



InBanBimmunocompetentBadult,BtheBlengthBofBincubationBforBtheBinfluenzaBvirusBisBonBavera
ge:B-BAnswer1-4Bdays



AdultsBpassBtheBillnessBonB1BdayBbeforeBtheBonsetBofBsymptomsBandBcontinueBtoBremainBin
fectiousBforBapproximatelyB5BdaysBafterBtheBonsetBofBtheBillness.BChildrenBremainBinfectiousB
forB10BorBmoreBdaysBafterBtheBonsetBofBsymptomsBandBcanBshedBtheBvirusBbeforeBtheBonse
tBofBsymptoms.BPeopleBwhoBareBimmunocompromisedBcanBremainBinfectiousBforBupBtoB3Bw
eeks.



InfluenzaBprotectionBoptionsBforBaB62-year-
oldBmanBwithBhypertension,Bdyslipidemia,BandBtypeB2BdiabetesBmellitusBincludeBreceiving:B-
BAnswertrivalentBinactivatedBvaccineB(TIV)BinBstandardBdoseBviaBintramuscularBinjection.



ThisBisBtheBtypicalB"fluBshot."BABquadrivalentBinactivatedBvaccineBisBalsoBavailable.



injectedBisBnotBliveBbutBtheBnasalBsprayBis



WhichBofBtheBfollowingBshouldBnotBreceiveBvaccinationBagainstBinfluenza?

A.BaB19Byear-oldBwithBaBhistoryBofBhive-formBreactionBtoBeatingBeggs

B.BaB24-year-oldBwomanBwhoBisB8BweeksBpregnantB

C.BaB4-month-oldBinfantBwhoBwasBbornBatB32BweeksBofBgestation

D.BaB28-year-oldBwomanBwhoBisBbreastfeedingBaB2BweekBold.B-BAnswerc



allBmembersBofBtheBpopulationBageB6BmonthsBandBolderBshouldBreceiveBannualBimmunizatio
nBagainstBseasonalBinfluenza.



thoseBwithBanBeggBallergyBthatBisBonlyBhivesBshouldBbeBgivenBtheBvax



ABhealthyB6-year-
oldBgirlBpresentsBforBcare.BHerBparentsBrequestBthatBsheBreceiveBvaccinationBforBinfluenzaBan
dBreportBthatBsheBhasBnotBreceivedBthisBvaccineBinBtheBpast.BHowBmanyBdosesBofBinfluenza
BvaccineBshouldBsheBreceiveBthisBfluBseason?

A.1BB.2BC.3BD.4B-BAnswerb

,AllBchildrenBagedB6BmonthsBtoB8ByearsBwhoBreceiveBaBseasonalBinfluenzaBvaccineBforBtheBfir
stBtimeBshouldBreceiveB2BdosesBspacedB≥4BweeksBapart.



highBriskBpopulationsBthatBneedBfluBvaxB-BAnswer•BAllBchildrenBagedB6BthroughB59Bmonths.

•BAdultsBandBchildrenBwhoBhaveBchronicBpulmonaryB(includingBasthma)BorBcardiovascularB(ex
ceptBisolatedBhypertension),Brenal,Bhepatic,Bneurological,Bhematologic,BorBmetabolicBdisorders
B(includingBdiabetesBmellitus).BIndividualsBageB50ByearsBofBageBandBolder.

•BPersonsBwhoBhaveBimmunosuppressionB(includingBimmunosuppressionBcausedBbyBmedicatio
nsBorBbyBHIVBinfection).

•BWomenBwhoBareBorBwillBbeBpregnantBduringBtheBinfluenzaBseason.

•BChildrenBandBadolescentsB(agedB6BmonthsB-B18Byears)BwhoBareBreceivingBlong-
termBaspirinBtherapyBandBwhoBmightBbe

atBriskBforBexperiencingBReye'sBsyndromeBafterBinfluenzaBvirusBinfection.

•BResidentsBofBnursingBhomesBandBotherBlong-termBcareBfacilities.

•BAmericanBIndians/AlaskaBNatives.

•BPersonsBwhoBareBmorbidlyBobeseB(BMIB≥40)Bkg/m2.

•BPeopleBwhoBliveBwithBorBcareBforBthoseBatBhighBriskBforBcomplicationsBfromBflu,Bincluding:

•BHealthcareBworkers.

•BHouseholdBcontactsBofBpersonsBwithBmedicalBconditionsBthatBputBthemBatBhighBriskBforBco
mplicationsBfromBtheBflu.

•BHouseholdBcontactsBandBoutBofBhomeBcaregiversBofBchildrenBagedB≤59BmonthsBandBadults
BagedB≥50Byears,BwithBpar-

ticularBemphasisBonBvaccinatingBcontactsBofBchildrenBlessBthanB6BmonthsBofBage.B(TheseBchil
drenBareBtooByoungBtoBbeBvaccinated.)



LAIVBisBapprovedBfor___B-
BAnswerLAIVBisBapprovedBforBuseBinBhealthyBpeopleBagesB2BtoB49ByearsBold



ItBisBnotBforBpatientsBwithBaBhealthBconditionBthatBplacesBthemBatBhighBriskBforBcomplicatio
nsBfromBinfluenza,BincludingBchronicBheartBdisease,BchronicBlungBdis-
BeaseBsuchBasBasthmaBorBreactiveBairwaysBdisease,BdiabetesBorBkidneyBfailure,BandBimmunos
uppression;BchildrenBorBadolescentsBreceivingBlong-termBhigh-
doseBaspirinBtherapy;BpeopleBwithBaBhistoryBofBGuillain-
BarréBsyndrome;BpregnantBwomen;BandBpeopleBwithBaBhistoryBofBallergyBtoBanyBofBtheBcom
ponentsBofBLAIV.BAdverseBeffectsBofBLAIVBincludeBnasalBirritationBandBdischarge,BmuscleBache
s,BsoreBthroat,BandBfever.

, FDABapprovedBantiviralBdrugsBforBfluB-
BAnswerInBtheBUnitedBStates,BfourBantiviralBdrugsBareBapprovedBbyBtheBFoodBandBDrugBAdm
inistrationB(FDA)BforBuseBagainstBinfluenza:BamantadineB(Symmetrel),BrimantadineB(Flumadine),
BzanamivirB(Relenza),BandBoseltamivirB(Tamiflu).



whichBfluBdrugsBareBonlyBforBinfluenzaBABandBwhatBareBtheBnewBreccsBforBthemB-
BAnsweramantadineB(Symmetrel),BrimantadineB(Flumadine)



highBlevelsBofBresistanceBofBinfluenzaBABvirusesBtoBamantadineBandBsimilarBmedications.BBeca
useBofBthisBsignificantBlevelBofBresistance,BamantadineBandBrimantadineBareBnoBlongerBrecom
mendedBbyBtheBCDCBforBtheBtreatmentBofBinfluenza.



adverseBaffectsBofBtheB2BmainBfluBantiviralBdrugsB-
BAnswerZanamivirBisBinhaledBandBcanBcauseBbronchospasm,BespeciallyBinBpatientsBwithBasthm
aBorBotherBchronicBlungBdisease.B



TheBadverseBeffectsBofBoseltamivirBareBlargelyBgastrointestinal;BtheBriskBofBnauseaBandBvomiti
ngBisBsignificantlyBreducedBifBtheBmedicationBisBtakenBwithBfood.



WhenBconsideringBanBadult'sBriskBforBmeasles,Bmumps,BandBrubellaB(MMR),BtheBNPBconsider
sBtheBfollowing:BA.BPatientsBbornBbeforeB1957BhaveBaBhighBlikelihoodBof

immunityBagainstBtheseBdiseasesBbecauseBofBaBhistory

ofBnaturalBinfection.

B.BConsiderableBmortalityBandBmorbidityBoccurBwithBall

threeBdiseases.

C.BMostBcasesBinBtheBUnitedBStatesBoccurBinBinfants.

D.BTheBuseBofBtheBMMRBvaccineBisBoftenBassociatedBwithBprotractedBarthralgia.B-BAnswerA



TheBMMRBvaccineBcontainsBliveBbutBweakenedB(attenuated)Bvirus.B



TwoBimmunizationsB1BmonthBapartBareBrecommendedBforBadultsBbornBafterB1957BbecauseBa
dultsBbornBbeforeBthenBareBconsideredBimmuneBasBaBresultBofBhavingBhadBtheseBdiseases(na
tiveBorBwildBinfection);BvaccineBagainstBtheseBthreeBformerlyBcommonBillnessesBwasBunavailab
leBuntilBtheB1960s